Moving back to the case report by Stryckers et al. [1], the rapid remission of NS upon discontinuation of guselkumab treatment strongly suggests a plausible causal link between IL-23 inhibitor therapy and FSGS development. The gene discussed is IL37; the disease is focal segmental glomerulosclerosis.